Health Trials

Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma

2

Review clinical trials related to Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.

Participants needed: 100
Trial details
Phase: Phase 2Age: 14+Biological sex: AllType: InterventionalSponsor: José Claudio Casali da RochaUpdated: Sep 11, 2025Locations: 1
Eligibility criteria

Age ≥ 14 years. [+6]

Age < 14 years. [+12]

Read more
Status: Recruiting

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

Participants needed: 60
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.Updated: Aug 14, 2024Locations: 1
Eligibility criteria

Male or female from 18 to 80 year-old [+6]

Hypoxia-induced factor inhibitors [+14]

Read more